Nanjing Leads Biolabs Co.,ltd

This early-phase study tested a new drug called LBL-007 combined with two other medications (toripalimab and axitinib) in 79 people with advanced melanoma that could not be removed by surgery or had spread. The main goals were to check safety and find the best dose. Researchers a…

This early-stage study tested a new drug called LBL-019, given alone or with another cancer drug (anti-PD-1), in 26 adults with advanced cancers that had stopped responding to standard treatments. The main goals were to check safety, how the drug moves through the body, and wheth…

This early-phase trial tested a new drug called LBL-033 in 26 adults with advanced solid tumors that had not responded to other treatments. The main goals were to check safety, find the best dose, and see if the drug could shrink or control the cancer. The study is now complete, …

This study tested a combination of two experimental drugs, LBL-007 and tislelizumab, in 98 adults with advanced solid tumors. The main goals were to find safe doses and see if the drugs could shrink tumors. The trial was completed and focused on safety and early signs of effectiv…